VOLUME 2 (2011)
View Archive »
About The Cover
PKM2 contributes to metabolic reprogramming and cancer progression by serving as a PHD3-dependent coactivator for HIF-1. Prolyl hydroxylation of PKM2 by PHD3 promotes the interaction of PKM2 with HIF-1α, thereby stabilizing HIF-1 binding to the HRE of target genes, recruitment of coactivator p300, histone acetylation, and subsequent transcription of HIF-1 target genes, which encode proteins that are involved in metabolic reprogramming, angiogenesis, and many other critical aspects of cancer progression. See Luo and Semenza.
|
|
Table of Contents
Editorial
|
| Allogeneic adoptive cell transfer therapy as a potent universal treatment for cancer |
|
https://doi.org/10.18632/oncotarget.300
|
| 525-526 |
|
| Paracrystals of STAT proteins and their dissolution by SUMO: How reduced transcription factor solubility increases cytokine signaling |
|
https://doi.org/10.18632/oncotarget.307
|
| 527-528 |
Research Papers
|
| A breast cancer metaanalysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables |
|
https://doi.org/10.18632/oncotarget.298
|
| 529-537 |
|
| Involvement of Akt1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy |
|
https://doi.org/10.18632/oncotarget.302
|
| 538-550 |
Research Perspectives
|
| Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxiainducible factor 1 in cancer cells |
|
https://doi.org/10.18632/oncotarget.299
|
| 551-556 |
|
| Targeting cancer with peptide aptamers |
|
https://doi.org/10.18632/oncotarget.297
|
| 557-561 |
|
| Targeting invadopodia to block breast cancer metastasis |
|
https://doi.org/10.18632/oncotarget.301
|
| 562-568 |
|
| Wnt and Kras signalingdark siblings in lung cancer |
|
https://doi.org/10.18632/oncotarget.305
|
| 569-574 |
|
| Evi1 forms a bridge between the epigenetic machinery and signaling pathways |
|
https://doi.org/10.18632/oncotarget.304
|
| 575-586 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß